Recro Pharma Other Current Liabilities

Recro Pharma (REPH) currently reports a other current liabilities of $11M as of December 2023. That compares with $13M in the prior-year period — down 14.8% year over year. Use the charts on this page to explore Recro Pharma's other current liabilities history and peer comparisons.

Recro Pharma's other current liabilities decreased from $13M to $11M — a 14.8% year-over-year decrease (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Recro Pharma reported $11M in other current liabilities as of December 2023. That compares with $13M in the prior-year period — down 14.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Recro Pharma, and consider following REPH for alerts when major investors trade the stock.

Recro Pharma is classified in the Healthcare sector. On other current liabilities, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing REPH with unrelated industries.